|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 29.76 USD | +4.83% |
|
+11.25% | +7.36% |
| 08-19 | Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder | RE |
| 08-05 | BofA Adjusts Price Target on Beam Therapeutics to $43 From $47 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAM THERAPEUTICS INC. | Other Biotechnology & Medical Research | +4.83% | +11.25% | +7.36% | +78.85% | -72.05% | 2.97B |  |  | |
- Stock Market
- Stocks
- BEAM Stock
- Charts Beam Therapeutics Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
